The comprehensive positive data across PWS, HO, and BBS strengthens the MC4R agonist thesis and supports Phase 3 advancement in PWS, which could open a new multi-thousand-patient market. Traders should watch for the company's Phase 3 initiation timeline for PWS and any subsequent regulatory feedback.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 16 $89.72entry
- T+1 · 5mo ago +6.81%α +8.06% · $95.83
- T+5 · 5mo ago +18.36%α +20.59% · $106.19
- T+20 · 4mo ago +22.56%α +22.36% · $109.96
- T+60 · 2mo ago +13.91%α +12.91% · $102.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
On June 13 and June 15, 2026, Rhythm Pharmaceuticals released positive interim clinical data from its Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS) and multiple data presentations across acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS), and PWS at ENDO 2026. Six-month PWS data showed a -3.06% mean BMI reduction, preservation of lean mass, and clinically meaningful hyperphagia improvements, with 8 of 10 moderate-to-severe patients achieving a ≥7-point HQ-CT reduction. Additional data showed -18.9% mean BMI reduction at 2.5 years in HO with setmelanotide, encouraging 1-year oral bivamelagon data in HO, and real-world BBS outcomes. The company confirmed plans to advance into Phase 3 trials for PWS, reinforcing the MC4R agonism thesis and expanding the addressable market opportunity.
Key Facts
- Setmelanotide in PWS: -3.06% mean BMI reduction at Month 6 (N=17); 8/10 moderate-to-severe hyperphagia patients achieved ≥7-point HQ-CT improvement
- Setmelanotide in acquired HO: -18.9% mean BMI reduction sustained at 2.5 years (n=11)
- Oral bivamelagon in HO: mean BMI reductions of 6.7% to 16.6% across dosing cohorts at Week 52 (n=26)
- Real-world BBS data (n=286): 62% of adults achieved ≥10% body weight loss at 12 months; significant reduction in outpatient obesity-related visits
- BBS RESTORE study (n=22): 93% reported no nighttime hunger after 6 months; use of other anti-obesity medications decreased by 25%
- Company estimates U.S. PWS addressable prevalence at 8,500-12,750 patients, with similar numbers in Europe
- Safety profile consistent with known setmelanotide tolerability across all indications
Financial Impact
Positive clinical data across PWS and HO support pipeline expansion into Phase 3 for PWS, a new indication with estimated addressable prevalence of 8,500-12,750 patients each in U.S. and Europe, potentially doubling or more the total addressable market for setmelanotide beyond current approved indications. No financial figures provided in the filing.
Risk Factors
- Phase 3 PWS trial design, enrollment, and execution risks remain; setmelanotide is already approved for HO and BBS
- Safety signals (injection site reactions, skin pigmentation, nausea) are well-characterized but may affect compliance in long-term use
- Potential competitive landscape for MC4R agonists in PWS
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-043170 |
| Exhibit: ex991rytmprpwsatendo2026.htm | 0001628280-26-043170 |
| Exhibit: ex992pwsatendo2026.htm | 0001628280-26-043170 |
| Document: 0001628280-26-043170-index-headers.html | 0001628280-26-043170 |
| Document: 0001628280-26-043170-index.html | 0001628280-26-043170 |
| Document: 0001628280-26-043170.txt | 0001628280-26-043170 |
Track record
26 reports on RYTM
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers